Zacks Investment Research·1 day ago
Is the Options Market Predicting a Spike in Adherex Technologies Stock?Investors need to pay close attention to FENC stock based on the movements in the options market lately.
Fennec Pharmaceuticals Inc.(FENC)Earnings, Financials & Key Ratios
FENC•NASDAQ
$10.50
Price updated Jul 7, 2026
AboutFennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.Show more
- Revenue$45M-6.1%
- EBITDA-$6M-290.4%
- Net Income-$10M-2134.2%
- EPS (Diluted)-0.36-2150.0%
- Gross Margin91.57%-1.9%
- EBITDA Margin-13.98%-302.7%
- Operating Margin-14.22%-372.6%
- Net Margin-21.82%-2279.0%
- ROE-66.77%
FENC Price & Volume
Fennec Pharmaceuticals Inc. (FENC) stock price & volume — 10-year historical chart
Loading chart...
Volatile PEDMARK Commercialization Masks Structural Liquidity Risks
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and dilution risk
Key Thesis Takeaways
- Fennec Pharmaceuticals faces a challenging path to profitability as the inconsistent adoption of PEDMARK continues to drive erratic revenue growth, which reached 72.6% in 2026Q1 after significant prior volatility.
- While the company has successfully eliminated its debt burden, the persistent reliance on stock-based compensation—totaling $2.5 million in 2025Q4—and the lack of sustained operating leverage suggest that the current commercial infrastructure remains inefficient.
- Investors should monitor whether the recent $24.8 million in deferred revenue can stabilize the balance sheet or if the company will require further dilutive financing to support its long-term operations.
Verdict Logic
the company's inability to generate consistent operating cash flow, combined with a forward P/E of 44.38, suggests that the current valuation does not adequately reflect the ongoing liquidity and dilution risks.
FENC Growth Metrics
Fennec Pharmaceuticals Inc. (FENC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years204.69%
3 Years207.52%
TTM64.98%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM41.99%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM39.69%
Return on Capital
10 Years-63.79%
5 Years-48.35%
3 Years-22.36%
Last Year-13%
FENC Recent Earnings
Fennec Pharmaceuticals Inc. (FENC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$0.01+150.0%
$0.02
Rev
$15M+8.6%
$14M
Q2 2026
Mar 24, 2026Metric
Actual
Est
EPS
$0.11-466.7%
$0.03
Rev
$14M-6.5%
$15M
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.02+75.0%
$0.08
Rev
$12M-15.2%
$15M
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.11-83.3%
$0.06
Rev
$10M+0.9%
$10M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.01vs $0.02+150.0% | $15Mvs $14M+8.6% |
| Q2 2026 | Mar 24, 2026 | $0.11vs $0.03-466.7% | $14Mvs $15M-6.5% |
| Q4 2025 | Nov 13, 2025 | $0.02vs $0.08+75.0% | $12Mvs $15M-15.2% |
| Q3 2025 | Aug 14, 2025 | $0.11vs $0.06-83.3% | $10Mvs $10M+0.9% |
Based on last 12 quarters of dataView full earnings history →
Latest FENC News
Recent stock market news and headlines for Fennec Pharmaceuticals Inc. (FENC)
GlobeNewsWire·Jun 22, 2026
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)RESEARCH TRIANGLE PARK, N.C., June 22, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026, the Compensation Committee of the Company's Board of Directors approved the grant of incentive stock option awards (“ISOs”) to purchase an aggregate of 15,000 of the Company's common shares to one new non-executive employee of the Company with a grant date of June 22, 2026 under the Company's 2026 Equity Inducement Plan (the “Inducement Plan”). The ISOs were granted as inducements material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Peers Comparison
Key metrics vs top competitors for Fennec Pharmaceuticals Inc. (FENC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.50 | $300.09M | -29.17 | -6.09% | -21.82% | -66.77% | — | |
| $1.32 | $329.07M | -4.71 | 53.24% | -434.44% | -156.65% | — | |
| $1.23 | $2.07M | -0.65 | 36.68% | -16.26% | -88.38% | — | |
| $81.57 | $9.68B | 31.86 | 37.55% | 23.13% | 126.27% | — | |
| $47.41 | $2.73B | -69.72 | 8.63% | -3.74% | -2.73% | — | |
| $89.20 | $7.4B | 11.47 | 114.51% | -22.58% | — | — |
Compare FENC vs Peers
Fennec Pharmaceuticals Inc. (FENC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
FENC SEC Filings & Documents
Fennec Pharmaceuticals Inc. (FENC) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 22, 2026·SEC
Material company update
May 18, 2026·SEC
Material company update
Apr 28, 2026·SEC
10-K Annual Reports
310-Q Quarterly Reports
6Get notified when FENC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
FENC Frequently Asked Questions
Fennec Pharmaceuticals Inc. (FENC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Fennec Pharmaceuticals Inc.'s revenue?
Fennec Pharmaceuticals Inc. (FENC) reported $51.0M in revenue for fiscal year 2025.
How fast is Fennec Pharmaceuticals Inc. growing?
Fennec Pharmaceuticals Inc. (FENC) saw revenue decline by 6.1% over the past year.
Is FENC profitable?
Fennec Pharmaceuticals Inc. (FENC) reported a net loss of $8.4M for fiscal year 2025.
Dividend & Returns
What is FENC's return on equity?
Fennec Pharmaceuticals Inc. (FENC) has a return on equity (ROE) of -66.8%. Negative ROE indicates the company is unprofitable.
What is Fennec Pharmaceuticals Inc.'s free cash flow?
Fennec Pharmaceuticals Inc. (FENC) had negative free cash flow of $5.8M in fiscal year 2025, likely due to heavy capital investments.